The size of the Europe Active Pharmaceutical Ingredients Market was valued at USD 48.64 billion in 2020, growing at a CAGR of 8.02% from 2021 to 2026.
The European active pharmaceutical ingredients market is primarily driven by chronic diseases, increasing research and development activities on pharmaceutical ingredients, and advancing biopharmaceuticals in Europe. The increasing geriatric population is more prone to cardiovascular diseases, diabetes, arthritis, asthma, and other chronic obstructive pulmonary diseases. Over the years, these chronic disorders have increased in the geriatric population in the developed countries such as UK, Germany, France, and Italy. In addition, changes in lifestyles and dietary habits brought on by urban development are likely to impact market development. Increasing cardiovascular disorders, cancer, and advancing the manufacturing of active pharmaceutical Ingredients in Europe is expected to augment the European API market growth.
Furthermore, a loss of physiological functions increases the chance of developing diseases such as CVD and diabetes; therefore, the Antibody Drug Conjugates usually utilize APIs in their composition (ADCs). However, market growth is being driven by changes in geopolitical situations. The favorable reimbursement policies for developing active pharmaceutical ingredients and advancing healthcare infrastructure drive the market in the European countries. Considering ADCs are important and successful cancer therapeutic modalities utilized in combination with clinically active medicines and monoclonal antibodies, the development of cancer-specific APIs is projected to boost the API market even more. Moreover, initiatives, increasing investments, and funding by the government and private organizations encourage market growth.
However, a lack of understanding of using active substances in the correct dosage restricts the European active pharmaceutical ingredients market growth. The most problematic aspect of market demand is the government's strict laws and regulations for pharmaceutical enterprises. In addition, the use of costly and unusual building blocks and raw materials in API chemical synthesis drives up API production costs further. However, the development of these APIs requires substantial investments, which are unaffordable in underdeveloped nations. The high manufacturing cost of APIs and unfavorable drug pricing policies in underdeveloped countries are likely to impede market growth.
Impact of COVID-19 on Europe Active Pharmaceutical Ingredients Market:
The emergence of covid-19 has impacted market growth. The supply chain had been disrupted. As a result, the European market was negatively impacted. Owing to the rapid disease transmission, the nationwide lockdown has been imposed. Major pharmaceutical companies and biopharmaceutical companies, and start-ups have been coming forward to develop a vaccine for the covid-19. However, drug makers are conducting research and development activities on drug manufacturing, focussing on the rapid patient population. Also, government initiatives for the eradicating the disease, making investments on pharmaceutical drug development institutions. However, the surge in chronic diseases across Europe is estimated to create demand for the market and most likely to have significant growth in the coming years.
This research report on the European active pharmaceutical ingredients market has been segmented and sub-segmented into the following categories.
By Type of Manufacturing Process:
By Type of Synthesis:
By API Formulation:
Geographically, the European API market accounted for a significant share in the global active pharmaceutical ingredients market in 2020. The market growth is driven by growing government focus on generic drugs and technological advancements in the manufacturing process of active pharmaceutical ingredients. Also, the increasing prevalence of various chronic disorders and rising demand for active pharmaceutical ingredients market is propelling the market in Europe. The presence of developed economies such as the UK, Germany, France, and Spain increase the regional market. In addition, collaborations and acquisitions expand the regional market growth. The UK is expected to contribute a significant share of active pharmaceutical ingredients to the growth of the European regional market. Advancing healthcare infrastructure and the adoption of technological advancements in API are driving the market. In addition, the launch of drugs and biological products increases market growth. Germany is a promising country in Europe, having a significant share in active pharmaceutical ingredients during the forecast period. Research and development activities conducted on API are showing market growth.
KEY MARKET PLAYERS:
AbbVie Inc., AstraZeneca, Aurobindo Pharma Ltd., BASF, Bayer AG, Boehringer Ingelheim, Dr. Reddy's Laboratories, F. Hoffmann-La Roche, GlaxoSmithKline plc, Lonza Group, Lupin Limited, Merck & Co., Inc., Mylan NV, Novartis International AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd are a few of the notable companies in the European active pharmaceutical ingredients market.